Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
| Autor: | Stephen C. Harris, Peter J. Perrino, Megan J. Shram, Yi Wang, Cynthia Bartlett, Salvatore V. Colucci |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Adult
Male Recreational Drug Adolescent medicine.drug_class Young Adult Double-Blind Method Reward Naloxone medicine Humans Pharmacology (medical) Original Research Article Oxycodone/naloxone Cross-Over Studies business.industry Chronic pain General Medicine Middle Aged medicine.disease Opioid-Related Disorders Crossover study Analgesics Opioid Drug Combinations Opioid Anesthesia Injections Intravenous Female business Oxycodone Opioid antagonist medicine.drug |
| Zdroj: | Clinical Drug Investigation |
| ISSN: | 1173-2563 |
| DOI: | 10.1007/s40261-014-0192-3 |
| Popis: | Background and Objective Abuse of opioid analgesics has become a public health issue. Some opioid abusers use intravenous administration to increase the magnitude of positive reinforcing effects. Intravenous co-administration of oxycodone with naloxone, an opioid antagonist, may reduce these rewarding effects and discourage abuse. A 2:1 oxycodone:naloxone (OXN) tablet formulation has been studied in the USA for the management of moderate-to-severe chronic pain. Intravenous administration of a 2:1 oxycodone:naloxone solution (sOXN) reflects the oxycodone:naloxone ratio found in laboratory studies of OXN following tampering for intravenous administration. The objective of this study was to characterize abuse-deterrent properties of sOXN. Methods This single-center, double-blind, randomized, placebo-controlled, active-controlled, crossover study enrolled nondependent recreational opioid users with experience using multiple (two or more) routes of administration. Following demonstration that subjects could discern between placebo and oxycodone, 24 eligible male and female subjects were randomized to receive intravenous injections of 0.07 mg/kg oxycodone (OXY), 0.07 mg/kg oxycodone and 0.035 mg/kg naloxone solution (sOXN), or matching placebo over three visits. Pharmacokinetics, pharmacodynamics, safety, and tolerability were assessed at scheduled times up to 8 h post-dose. Parameters were computed and statistically compared among treatments. Results Pharmacokinetics were similar between OXY and sOXN. Subjects reported significantly fewer rewarding effects with sOXN compared with OXY; differences between sOXN and placebo were generally not significant. sOXN was well tolerated. Conclusions Significant reductions in drug liking and other subjective effects following administration of sOXN compared with OXY indicate that naloxone concentrations were sufficient to antagonize the effects of oxycodone when abused by the intravenous route of administration in opioid-experienced drug users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|